Recently, another investigation appearing in the journal Retina evaluated how the popular drug impacts the risk of AMD development and progression, specifically among patients with type 2 diabetes
Implication: The Regeneron/Hansoh deal was smaller than Metsera but signals another trend: companies are grabbing novel dual/triple agonizers wherever they arise
Nausea hits 36.9% of GLP-1 users per Nature Healths 2026 analysis of 67,008 self-reporters
Light to moderate aerobic exercise (walking, swimming, cycling) is ideal
While this anti-diabetic medication has been shown to increase the release of GLP-1, it does so indirectly and not by direct impact on the intestinal cells
Your dose may increase over time, but your monthly price remains unchanged